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Rehabilitation treatments and services are an 
important part of the healthcare system, and 
the need for such services is increasing. A larger 
proportion of the population is aging or elderly 
and, thanks to advances in medical technology, a 
number of individuals with disability who might 
previously have died are enjoying improved 
survival rates.1 Rehabilitation treatments are 
important both economically and in terms of 
quality of life, and can be expected to become 
more critical in the future.1 
Despite their importance, evidence supporting the 
efficacy and effectiveness of most rehabilitation 
treatments is sparse. There are many reasons 
for this, including inadequate funding of 
rehabilitation research, insufficient numbers of 
rigorously trained investigators, and the inherent 
complexity of the biopsychosocial (as compared to 
the biomedical) model that underlies the practice 
of rehabilitation.2 However, an increasingly 
recognized obstacle to research is the difficulty 
in defining many rehabilitation treatments with 
respect to their “active ingredients” in such a 
way that their impact can be studied. Similar 
to psychotherapy—whose efficacy has also 
been challenging to study—most rehabilitation 
treatments are delivered through some form of 
interpersonal interaction between rehabilitation 
therapist and patient/client, may be tailored 
to the goals, strengths, and weaknesses of the 
individual, and may incorporate multiple active 
ingredients.3 For example, consider several 
patients with difficulty walking after a stroke. 
All may be receiving “gait training”, but in one 
case the emphasis may be more on correcting 
impaired balance; in another on clearing the 
toe with each step; and another on being more 
attentive to obstacles in the environment while 
walking. Are these all the same treatment or is 
each patient receiving a different treatment? 
Because of these complexities, many attempts 
at clinical rehabilitation research have resorted 
to defining the treatments merely as numbers 
of hours of physical, occupational, speech, and 
other therapies; length of stay in a particular type 
of institution; or the goal of the treatment (e.g., 
“attention training”), as though the actual services 
delivered by clinicians and institutions during 
the treatment time are unimportant. Although 
numbers of sessions or hours may certainly 
be relevant, just as the dose of a medication is 
important, the dose does nothing to define the 
active ingredients of the treatment.
Recently the National Institute on Disability 
and Rehabilitation Research (NIDRR), a major 
funding source for rehabilitation research, 
awarded a 5-year grant to Marcel Dijkers, PhD 
at Mount Sinai School of Medicine for a project 
entitled, “Classification and Measurement of 
Medical Rehabilitation Interventions.” This 
project is intended to begin a process of building 
a taxonomy of rehabilitation treatments that 
is suitable for research purposes and may also 
facilitate interdisciplinary communication, clinical 
education, documentation, and billing. The grant 
includes a subcontract to Moss Rehabilitation 
Research Institute (MRRI) at the Albert Einstein 
Healthcare Network, an affiliate of Thomas 
Jefferson University, with John Whyte, MD, PhD 
and Tessa Hart, PhD as lead investigators at MRRI.
A taxonomy is a way of dividing a set of entities—
in this case rehabilitation treatments—into a 
set of ordered groups or categories. Building a 
taxonomy of rehabilitation treatments that is 
applicable across disabilities, treatment settings, 
and patient populations is an enormous task 
that cannot be completed in a single grant 
cycle. The current project contains several key 
activities that are expected to support ongoing 
taxonomy development beyond the duration 
of the project. First is the construction of a 
“blueprint” for the taxonomy—an effort that will 
be led by the author. The blueprint will specify 
the principles by which treatments are grouped 
in the final taxonomy. In principle, one could sort 
rehabilitation treatments into categories according 
to whether the treatment was provided by a 
woman, a man, or a robot; whether the treatment 
was conducted in the morning or the afternoon; 
or an infinite number of other dimensions. The 
development of the blueprint will be shaped by 
reviewing published literature on a wide range 
of rehabilitation treatments and services, paying 
particular attention to overt or covert “treatment 
theory,” since treatment theory proposes the 
mechanism by which a treatment works. Thus, 
to the extent possible, the boundaries between 
treatment taxonomy categories should reflect the 
active ingredients of the treatments as opposed to 
dimensions that don’t bear on how the treatment 
will be used or how effective it will be. Upon 
completion of the blueprint, a multidisciplinary 
stakeholder conference will be held to review and 
critique the blueprint.
After the investigators obtain feedback from 
rehabilitation professionals and consumer 
advocacy groups, the blueprint will be tested by 
using it to construct treatment taxonomies in 
two focused areas: treatments to improve gait 
and mobility for individuals with neurologic 
impairments; and treatments to ameliorate 
executive function deficits in individuals 
with brain injury. The choice of exemplars is 
relatively arbitrary and reflects a desire to assess 
the blueprint’s capacity to guide organization 
of a more cognitive vs. more motor domain, 
and to use domains with which the research 
team is particularly knowledgeable. Taxonomy 
development in these two treatment areas may 
suggest further refinements of the blueprint itself, 
with the goal that, by the end of the five-year 
project, a relatively enduring blueprint will be 
published that can support further taxonomic 
development in many additional treatment 
areas. In the final stages of the project, the two 
taxonomies discussed above and the revised 
blueprint will be reviewed and critiqued by 
external stakeholders, and plans made to continue 
further development of a useful treatment 
taxonomy for rehabilitation.  
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